



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

02 March 2026
EMA/HMPC/30298/2026
Human Medicines Division

Committee on Herbal Medicinal Products (HMPC) Draft Agenda for the meeting on 02-04 March 2026

Chair: Carmen Purdel, Vice-Chair: Karin Erika Svedlund

02 March 2026, 13:00 – 18:00, room 2C

03 March 2026, 09:00 – 18:00, room 2C

04 March 2026, 09:00 – 16:00, room 2C

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed.

Of note, this agenda is a working document primarily designed for HMPC members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the [Agency policy on access to documents](#) (EMA/729522/2016).

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members, alternates and experts.....	5
1.2.	Adoption of agenda.....	5
1.3.	Adoption of the minutes	5
2.	EU herbal monographs and list entries for adoption	5
2.1.	Status of HMPC activities.....	5
2.1.1.	Overview of HMPC assessment work including the Rapporteurship distribution – Status in March 2026.....	5
2.1.2.	Appointment of Rapporteurs and Peer-reviewers	5
2.2.	Revised EU herbal monographs and list entries for final adoption	5
2.2.1.	Monograph on Liquiritiae radix and supporting documents	5
2.3.	Revised EU herbal monographs and list entries for public consultation	6
2.3.1.	Monograph on Lecithinum ex soya and supporting documents - postponed	6
2.4.	Reviewed EU herbal monographs and list entries for decision on revision.....	6
2.4.1.	Monograph on Centaurii herba and supporting documents	6
2.4.2.	Monograph on Rusci rhizoma and supporting documents	6
2.5.	EU herbal monographs, list entries and public statements for final adoption	6
2.6.	EU herbal monographs, list entries and public statements for adoption for release for public consultation.....	6
2.7.	EU herbal monographs, list entries and public statements - post finalisation.....	6
2.7.1.	Monograph on Hyperici herba/Cimicifugae rhizoma and supporting documents.....	6
3.	Referral procedures	6
4.	Guidelines and guidance documents	6
4.1.	Non-clinical/clinical safety and efficacy and multidisciplinary.....	6
4.1.1.	Guideline on the assessment of genotoxicity of herbal substances/preparations (EMA/HMPC/107079/2007)	6
4.2.	Quality.....	7
4.2.1.	Guideline on declaration of herbal substances and herbal preparations in herbal medicinal products/traditional herbal medicinal products (EMA/HMPC/CHMP/CVMP/287539/2005)	7
4.3.	Regulatory/Procedural	7
4.4.	Report on HMPC Drafting Groups activities.....	7
4.4.1.	ORGAM DG	7
4.4.2.	Quality DG.....	7
5.	Organisational, regulatory and methodological matters	7
5.1.	Mandate and organisation of the HMPC	7
5.1.1.	Strategic Review and Learning Meetings (SRLM).....	7
5.1.2.	HMPC membership.....	8
5.1.3.	Election of HMPC Vice-Chairperson.....	8

5.1.4.	HMPC - desired areas of expertise	8
5.2.	EMA Scientific Committees or CMDh-v	8
5.2.1.	HMPC/PRAC collaboration on signal detection: safety-assessment for herbal medicinal products.....	8
5.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	8
5.3.1.	HMPC/Translational Science Office collaboration: requirements for studying the interaction potential of herbal medicinal products	8
5.4.	Cooperation within the EU regulatory network.....	8
5.4.1.	European Pharmacopoeia	8
5.4.2.	European Food Safety Authority (EFSA).....	9
5.5.	Cooperation with International Regulators.....	9
5.5.1.	EU/India Technical Working Group on Ayurveda	9
5.6.	Contacts of the HMPC with external parties and interaction with the Interested Parties to the Committee	9
5.7.	Work plan and related activities	9
5.7.1.	Follow-up on HMPC work plan 2026	9
5.8.	Planning and reporting	10
5.8.1.	EMA/FDA Workshop on herbal medicines development	10
5.9.	Legislation and regulatory affairs	10
5.10.	Questions from members.....	10
6.	EU herbal monographs and list entries in preparation	10
6.1.	Revision of EU herbal monographs and list entries in preparation for adoption after public consultation	10
6.1.1.	Monograph on <i>Fragariae folium</i> and supporting documents.....	10
6.1.2.	Monograph on <i>Species diureticae</i> and supporting documents	10
6.2.	Revision of EU herbal monographs and list entries in preparation for public consultation.....	11
6.3.	Review of EU herbal monographs and list entries in preparation for decision on revision	11
6.3.1.	Monograph on <i>Anisi aetheroleum</i> and supporting documents.....	11
6.3.2.	Monograph on <i>Anisi fructus</i> and supporting documents	11
6.3.3.	Monograph on <i>Echinaceae angustifoliae radix</i> and supporting documents.....	11
6.3.4.	Monograph on <i>Eleutherococci radix</i> and supporting documents - postponed.....	11
6.3.5.	Monograph on <i>Myrrha</i> and supporting documents.....	11
6.3.6.	Monograph on <i>Salicis cortex</i> and supporting documents	11
6.3.7.	Monograph on <i>Salviae officinalis folium</i> and supporting documents	11
6.3.8.	Monograph on <i>Thymi herba</i> and supporting documents	11
6.4.	EU herbal monographs and list entries in preparation for adoption after public consultation.....	12
6.4.1.	Monograph on <i>Cannabis flos</i> and supporting documents	12

6.5.	EU herbal monographs and list entries in preparation for adoption for release for public consultation	12
6.5.1.	Monograph on Valerianae radix/Passiflorae herba and supporting documents	12
7.	Any other business	12
7.1.	Topics for discussion	12
7.1.1.	Herbal Summit 2026, 25 February, Brussels	12
7.1.2.	Pilot – transition to IRIS/SharePoint.....	12
7.2.	Documents for information	12
7.2.1.	HMPC	12
7.2.2.	Assessment Report Summary for the Public (ARSP)	12
7.2.3.	Other	13

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the HMPC plenary session to be held on 02-04 March 2026. See March 2026 HMPC minutes (to be published post May 2026 HMPC meeting).

1.2. Adoption of agenda

HMPC agenda for 02-04 March 2026.

1.3. Adoption of the minutes

HMPC minutes for 19-21 January 2026.

2. EU herbal monographs and list entries for adoption

2.1. Status of HMPC activities

2.1.1. Overview of HMPC assessment work including the Rapporteurship distribution – Status in March 2026

Report: HMPC Chair

Action: For discussion

Document tabled: Overview

2.1.2. Appointment of Rapporteurs and Peer-reviewers

Periodic reviews to start in 2026-2027

Report: HMPC Chair

Action: For discussion

Documents tabled: Overview document to sign-up as Rapporteur/Peer-reviewer; [Review/revision procedure](#)

2.2. Revised EU herbal monographs and list entries for final adoption

2.2.1. Monograph on Liquiritiae radix and supporting documents

Action: For adoption

Documents tabled: AR, MO, LoR, Reader's Guidance, References 0/335

2.3. Revised EU herbal monographs and list entries for public consultation

2.3.1. Monograph on Lecithinum ex soya and supporting documents - postponed

2.4. Reviewed EU herbal monographs and list entries for decision on revision

2.4.1. Monograph on Centaurii herba and supporting documents

Action: For adoption

Document tabled: Review report

2.4.2. Monograph on Rusci rhizoma and supporting documents

Action: For adoption

Document tabled: Review report

2.5. EU herbal monographs, list entries and public statements for final adoption

None

2.6. EU herbal monographs, list entries and public statements for adoption for release for public consultation

None

2.7. EU herbal monographs, list entries and public statements - post finalisation

2.7.1. Monograph on Hyperici herba/Cimicifugae rhizoma and supporting documents

Action: For adoption

Document tabled: OoC

3. Referral procedures

None

4. Guidelines and guidance documents

4.1. Non-clinical/clinical safety and efficacy and multidisciplinary

4.1.1. Guideline on the assessment of genotoxicity of herbal substances/preparations (EMA/HMPC/107079/2007)

Action: For discussion

Document tabled: EFSA email

4.2. Quality

4.2.1. Guideline on declaration of herbal substances and herbal preparations in herbal medicinal products/traditional herbal medicinal products (EMA/HMPC/CHMP/CVMP/287539/2005)

Report: Carmen Purdel

Action: For discussion

Document tabled: Draft revised guideline on declarations

4.3. Regulatory/Procedural

None

4.4. Report on HMPC Drafting Groups activities

4.4.1. ORGAM DG

None

4.4.2. Quality DG

- QDG February meeting
Report: Carmen Purdel
Action: For information
Document tabled: Minutes February 2026
- QDG Chairperson election May 2026
Report: Carmen Purdel
Action: For information

5. Organisational, regulatory and methodological matters

5.1. Mandate and organisation of the HMPC

5.1.1. Strategic Review and Learning Meetings (SRLM)

- HMPC SRLM Follow up plan - status March 2026
Report: HMPC Vice-chair
Action: For information
- Cypriot Presidency meeting June 2026
Report: Christina Sylvia Chrysostomou
Action: For information
Document tabled: SRLM draft agenda
- Irish Presidency meeting second half 2026

Report: Jacqueline Masterson

Action: For information

5.1.2. HMPC membership

Report: HMPC Chair

Action: For information

5.1.3. Election of HMPC Vice-Chairperson

Action: For adoption

Documents tabled: Call for expression of interest, Presentation, [HMPC RoP](#), Candidatures

5.1.4. HMPC - desired areas of expertise

Report: HMPC Chair

Action: For adoption

Documents tabled: HMPC areas of expertise, Email

5.2. EMA Scientific Committees or CMDh-v

5.2.1. HMPC/PRAC collaboration on signal detection: safety-assessment for herbal medicinal products

Action: For discussion

Document tabled: Draft Reflection paper

5.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

5.3.1. HMPC/Translational Science Office collaboration: requirements for studying the interaction potential of herbal medicinal products

Action: For discussion

Document tabled: Draft Reflection paper

5.4. Cooperation within the EU regulatory network

5.4.1. European Pharmacopoeia

- EDQM 13A expert group meeting

Report: Melanie Bald

Action: For information

Document tabled: SoD

- EDQM 13B expert group meeting

Report: Melanie Bald

Action: For information

Document tabled: SoD

- EDQM TCM expert group meeting

Report: Melanie Bald

Action: For information

Document tabled: SoD

5.4.2. European Food Safety Authority (EFSA)

Action: For information

5.5. **Cooperation with International Regulators**

5.5.1. EU/India Technical Working Group on Ayurveda

Report: HMPC Chair

Action: For information

5.6. **Contacts of the HMPC with external parties and interaction with the Interested Parties to the Committee**

None

5.7. **Work plan and related activities**

5.7.1. Follow-up on HMPC work plan 2026

Report: HMPC Chair

Action: For information

Document tabled: [HMPC work plan 2026](#)

- 1) Explore new initiatives for the use of real-world data (RWD) and opportunities to use digitalisation and artificial intelligence (AI) in support of decisions

Action: For discussion

Document tabled: Email

- 2) HMPC position on the role of European Union herbal monographs and assessment reports in relationship to borderline issues

Action: For discussion

Documents tabled: Draft Reflection Paper, OoC, Reader's Guidance

- 3) Development of guidance on particulars for signal detection for (traditional) herbal medicinal products

Action: For discussion

Document tabled: Presentation

- 4) Improve the evaluation of data from paediatric clinical practice for the safe use of herbal substances in children

Action: For discussion

Documents tabled: Draft Reflection Paper, OoC

- 5) HMPC communication of information on (traditional) herbal medicinal products to the public and stakeholders

Action: For adoption

Documents tabled: Summaries for the public on Hyperici herba, Pelargonii radix, Foeniculi amari fructus, Foeniculi dulcis fructus

- 6) Improve work-sharing in HMPC activities aiming at sustainability of the European medicines regulatory network (EMRN)

Action: For discussion

Document tabled: Presentation

5.8. Planning and reporting

5.8.1. EMA/FDA Workshop on herbal medicines development

Report: HMPC Chair

Action: For discussion

Document tabled: Draft program, [Botanical Drug Development Guidance for Industry](#)

5.9. Legislation and regulatory affairs

None

5.10. Questions from members

None

6. EU herbal monographs and list entries in preparation

6.1. Revision of EU herbal monographs and list entries in preparation for adoption after public consultation

6.1.1. Monograph on *Fragariae folium* and supporting documents

Action: For 1st discussion

Documents tabled: Draft AR, MO, LoR, Reader's Guidance

6.1.2. Monograph on *Species diureticae* and supporting documents

Action: For 1st discussion

Documents tabled: Draft AR, MO, LoR, Reader's Guidance

6.2. Revision of EU herbal monographs and list entries in preparation for public consultation

None

6.3. Review of EU herbal monographs and list entries in preparation for decision on revision

6.3.1. Monograph on Anisi aetheroleum and supporting documents

Action: For 2nd discussion

Document tabled: Review report, Reader's Guidance

6.3.2. Monograph on Anisi fructus and supporting documents

Action: For 2nd discussion

Document tabled: Review report, Reader's Guidance

6.3.3. Monograph on Echinaceae angustifoliae radix and supporting documents

Action: For 5th discussion

Document tabled: Review report

6.3.4. Monograph on Eleutherococci radix and supporting documents - postponed

6.3.5. Monograph on Myrrha and supporting documents

Action: For 3rd discussion

Document tabled: Review report

6.3.6. Monograph on Salicis cortex and supporting documents

Action: For 4th discussion

Document tabled: Review report

6.3.7. Monograph on Salviae officinalis folium and supporting documents

Action: For 5th discussion

Document tabled: Review report

6.3.8. Monograph on Thymi herba and supporting documents

Action: For 10th discussion

Document tabled: Review report

6.4. EU herbal monographs and list entries in preparation for adoption after public consultation

6.4.1. Monograph on Cannabis flos and supporting documents

Action: For 2nd discussion

Document tabled: OoC

6.5. EU herbal monographs and list entries in preparation for adoption for release for public consultation

6.5.1. Monograph on Valerianae radix/Passiflorae herba and supporting documents

Action: For 3rd discussion

Documents tabled: Draft MO, AR, LoR, Reader's Guidance

7. Any other business

7.1. Topics for discussion

7.1.1. Herbal Summit 2026, 25 February, Brussels

Action: For information

Document tabled: [Summit webpage](#)

7.1.2. Pilot – transition to IRIS/SharePoint

Action: For information

7.2. Documents for information

7.2.1. HMPC

Table of Decisions from HMPC meeting held on 19-21 January 2026

Overview of expertise of members HMPC and subgroups

[Inventory of herbal substances for assessment work](#)

[List of abbreviations used in EMA human medicines scientific committees & CMDh documents and in relation to EMA's regulatory activities](#)

Common names of herbal substances in all languages

Final Monograph Overview

Best practice guide on using HMPC plenary time efficiently (with annexed Reader's Guidance template)

7.2.2. Assessment Report Summary for the Public (ARSP)

None

7.2.3. Other

- Annual update of EMA DoI